IMNM Q2 2020 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$3M

Net Income

-$3M

EPS (Diluted)

$-0.29

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$39,000

Balance Sheet

Total Assets

$12M

Total Liabilities

$3M

Stockholders' Equity

$9M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$3M	-$2M	-14.6%
Net Income	-$3M	-$2M	-13.3%